Needham & Company Reiterates Jazz Pharmaceuticals (JAZZ) at Buy on Earnings, Analyst Doesn't Expect Stock to Uptick Short-Term, but Highlights Strong Execution and Fundamentals
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Buy rating and $215.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
